Factors that modify therapy adherence in patients with inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 4, Issue 4, 2010, Pages 422-426

  Bermejo, Fernando ^a   Román, Antonio López San ^b   Algaba, Alicia ^a   Guerra, Iván ^a   Valer, Paz ^a   García Garzón, Silvia ^a   Piqueras, Belén ^a   Villa, Carlos ^a   Bermejo, Andrea ^a   Rodríguez Agulló, José L ^a  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Adherence; Crohn's disease; Inflammatory bowel disease; Therapy; Ulcerative colitis

Indexed keywords

IMMUNOMODULATING AGENT; MESALAZINE;

ADULT; ARTICLE; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT REFUSAL; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT EDUCATION AS TOPIC;

EID: 77957295897     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.01.005     Document Type: Article

References (31)

1. Sewitch M.J., Abrahamowicz M., Barkun A., Bitton A., Wild G.E., Cohen A., et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003, 98:1535-1544.
2. Kane S., Huo D., Aikens J., Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Medicine 2003, 114:39-43.
3. Schroeder K., Fahey T., Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004, 164:722-732.
4. Pasternak R.C. Report of the Adult Treatment Panel III: the 2001 National Cholesterol Education Program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults. Cardiol Clin 2003, 21:393-398.
5. Levy R.L., Feld A.D. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999, 94:1733-1742.
6. Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008, 27(Suppl. 1):9-14.
7. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 170(Suppl):2-6.
8. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980 Mar 8, 1:514.
9. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955, 2:1041-1048.
10. Kane S.V., Cohen R.D., Aikens J.E., Hanauer S.B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001, 96:2929-2933.
11. Kane S.V. Systematic review: adherent issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006, 23:577-585.
12. Rubin G., Hungin A.P., Chinn D., Dwarakanath A.D., Green L., Bates J. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther 2002, 16:1889-1893.
13. López-Sanromán, Bermejo F., Carrera E., Pérez-Abad M., Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005, 97:249-257.
14. Bernal I., Domènech E., Garcia-Planella E., Marín L., Mañosa M., Navarro M., et al. Medication-taking behaviour in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006, 51:2165-2169.
15. Shale M.J., Riley S.A. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003, 18:191-198.
16. D'Incà R., Bertomoro P., Mazzocco K., Vettorato M.G., Rumiati R., Sturniolo G.C. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther 2008, 27:166-172.
17. Nguyen G.C., Laveist T.A., Harris M.L., Datta L.W., Bayless T.M., Brant S.R. Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:1233-1239.
18. Baars J.E., Zelinkova Z., Mensink P.B., Markus T., Looman C.W., Kuipers E.J., et al. High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patient organization: a patient empowerment study. Aliment Pharmacol Ther 2009, 30:864-872.
19. Hawthorne A.B., Rubin G., Ghosh S. Review article: medication non-adherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008, 27:1157-1166.
20. Waters B.M., Jensen L., Fedorak R. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol 2005, 19:235-244.
21. Velayos F.S., Terdiman J.P., Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2005, 100:1345-1353.
22. Van Staa T.P., Card T., Logan R.F., Leufkens H.G. Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005, 54:1573-1578.
23. López-Sanroman A., Bermejo F. Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2006, 24(Suppl 3):45-49.
24. Bokemeyer B., Teml A., Roggel C., Hartmann P., Fischer C., Schaeffeler E., et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007, 26:217-225.
25. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
26. Kruis W., Kiudelis G., Rácz I., Gorelov I.A., Pokrotnieks J., Horynski M., et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009, 58:233-240.
27. Dignass A.U., Bokemeyer B., Adamek H., Mross M., Vinter-Jensen L., Börner N., et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009, 7:762-769.
28. Kamm M.A., Lichtenstein G.R., Sandborn W.J., Schreiber S., Lees K., Barrett K., et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008, 57:893-902.
29. Hall N.J., Rubin G.P., Hungin A.P., Dougall A. Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. BMC Gastroenterol 2007, 7:20.
30. Robinson A., Thompson D.G., Wilkin D., Roberts C. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001, 358:976-981. Northwest Gastrointestinal Research Group.
31. Kennedy A.P., Nelson E., Reeves D., Richardson G., Roberts C., Robinson A., et al. A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut 2004, 53:1639-1645.